Drug Profile

Promethazine/sumatriptan - Charleston Laboratories

Alternative Names: CL-H1T; sumatriptan succinate/promethazine HCl - Charleston Laboratories

Latest Information Update: 21 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Charleston Laboratories
Class Amines; Antiemetics; Antimigraines; Indoles; Phenothiazines; Small molecules; Sulfonamides
Mechanism of Action Histamine H1 receptor antagonists; Muscarinic receptor antagonists; Serotonin 1D receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

21 Mar 2023 Promethazine/sumatriptan (CL H1T) is still in phase III trials for Migraine in USA (PO)
21 Mar 2023 Promethazine/sumatriptan (CL H1T) is still in phase III trials for Nausea and vomiting (Prevention) in USA (PO)
23 Feb 2021 Phase-III clinical trials in Migraine in USA (PO) (Charleston Laboratories pipeline, February 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com